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ABSTRACT
AATD is a common inherited disorder associated with an
increased risk of developing pulmonary emphysema and
liver disease. Many people with AATD-associated pulmo-
nary emphysema remain undiagnosed and therefore with-
out access to care and counselling speciﬁc to the disease.
AAT augmentation therapy is available and consists of
i.v. infusions of exogenous AAT protein harvested from
pooled blood products. Its clinical efﬁcacy has been the
subject of some debate and the use of AAT augmentation
therapy was recently permitted by regulators in Australia
and New Zealand, although treatment is not presently
subsidized by the government in either country. The pur-
pose of this position statement is to review the evidence
for diagnosis and treatment of AATD-related lung disease
with reference to the Australian and New Zealand popula-
tion. The clinical efﬁcacy and adverse events of AAT aug-
mentation therapy were evaluated by a systematic review,
and the GRADE process was employed to move from
evidence to recommendation. Other sections address the
wide range of issues to be considered in the care of the
individual with AATD-related lung disease: when and
how to test for AATD, changing diagnostic techniques,
monitoring of progression, disease in heterozygous AATD
and pharmacological and non-pharmacological therapy
including surgical options for severe disease. Consider-
ation is also given to broader issues in AATD that respira-
tory healthcare staff may encounter: genetic counselling,
patient support groups, monitoring for liver disease and
the need to establish national registries for people with
AATD in Australia and New Zealand.
Key words: alpha1-antitrypsin deﬁciency, augmentation ther-
apy, chronic obstructive pulmonary disease, emphysema.
INTRODUCTION
Alpha1-antitrypsin (AAT) deﬁciency (AATD) is an
inherited disease that causes the production of defective
AAT and low circulating blood levels of functioning
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AAT. This results, most commonly, in an increased sus-
ceptibility to pulmonary emphysema and liver cirrhosis.
Rarer associations are necrotizing panniculitis and
granulomatosis with polyangiitis while glomerulonephri-
tis, inﬂammatory bowel disease and vascular aneurysm
are possible associations.1–3
AAT is a member of the serpin superfamily of pro-
teins, it is synthesized in the liver and acts as an irre-
versible proteinase inhibitor to protect tissues from the
actions of inﬂammatory proteins, particularly neutro-
phil elastase. Protein synthesis is coded by two codom-
inant alleles and, while many alleles have been
detected within the human population, the most com-
mon are PiM (normal), PiS and PiZ, and pairings of
these account for >99% of genotypes. Circulating AAT
concentrations below 1.1 g/L usually deﬁne individuals
with at least one deﬁciency allele and levels are
reduced below 0.5 g/L in the most common AATD
genotype, PiZZ.4
In Australia and New Zealand, the best information
available suggests that the gene frequency for the PiZ
allele is 13 and 22 per 1000, respectively.5 This equates
to similar predicted numbers of the severe form of
PiZZ AATD as in North America of 1 in 2500 to 1 in
5000.6 The frequency of the PiZ allele is reduced in
most Asian populations and may be increased in
Maori compared to New Zealand Europeans.7 The less
severely deﬁcient PiS allele frequency is estimated to
be 44 and 39 per 1000 in Australia and New Zealand,
respectively.8
It is estimated that there are in excess of 30 000 indi-
viduals across Australia and New Zealand with
AATD.9,10 Many remain undiagnosed either because of
a lack of clinical manifestation of their deﬁciency or
through being unrecognized by their treating physi-
cians. It has been reported, based upon allelic frequen-
cies, that less than 10% of AATD individuals are
diagnosed, while 1% of all patients with chronic
obstructive pulmonary disease (COPD) have AATD.11–15
Understanding of the natural history of AATD is
incomplete but the role of cigarette smoking is cru-
cial.16,17 There is some evidence that, while never-
smoking individuals with AATD have an increased risk
of developing COPD, they have a similar survival time
to the general population.17–19 Smoking individuals with
AATD develop COPD 10–20 years earlier than smokers
with normal AAT levels and they have a median sur-
vival time approximately 15 years less than their non-
smoking AATD counterparts.18,20
Elements of care for the pulmonary manifestations of
AATD for consideration by the clinician include usual
care of COPD, surgical options and AAT augmentation
therapy (regular infusion of AAT to increase an individ-
ual’s blood levels above a threshold proposed to protect
against lung disease). AAT augmentation therapy has
been available in the United States and elsewhere for
many years.21 Its clinical efﬁcacy has been the subject of
some debate22 and the use of AAT augmentation therapy
was recently permitted by regulators in Australia and
New Zealand, although treatment is not presently subsi-
dized by the government in either country.
The purpose of this position statement is to provide
information to clinicians on the investigation and treat-
ment of AATD and it does not represent a guideline. It
is divided into four sections covering (i) diagnosis,
(ii) AAT augmentation therapy, (iii) surgical options and
(iv) other pharmacological and non-pharmacological
care of COPD written in a question-and-answer format.
This position statement is endorsed by the Thoracic
Society of Australia and New Zealand (TSANZ) and will
be disseminated through publication in Respirology. The
clinical relevance of this document will be reviewed at
5 years from publication.
METHODS
To create the position statement, J.D. was appointed
to chair a working group of 14 members selected for
their expertise in the diagnosis and treatment of AATD
and COPD. The working group comprised eight respi-
ratory physicians, a respiratory nurse, a respiratory
scientist, a hepatologist, a cardiothoracic surgeon, a
pharmacoepidemiologist and one patient representa-
tive, and there was representation from across
Australia and New Zealand. Two patient representa-
tives were added after the initial draft of the manu-
script for participation in the GRADE (Grading of
Recommendations, Assessment, Development and
Evaluations) panel. The panel worked with a method-
ologist, A.E.H., who is a physiotherapist. The method-
ologist prepared evidence summaries for the AAT
augmentation section and participated in discussions
but did not vote on recommendations. The majority
of the working group did not have a conﬂict of inter-
est and the working group did not receive any com-
mercial sponsorship. In initial meetings, we developed
and agreed principles for managing conﬂicts of inter-
est (Appendix S1 in Supplementary Information),23,24
we deﬁned the scope of the position statement and
we assigned sections to writing groups. Each writing
group undertook a comprehensive literature review
for their section. The sections were collated into a
manuscript and all members of the working group
and two additional patient representatives then had
the opportunity to contribute to and review the entire
document.
Because we anticipated there would be a variety of
views on AAT augmentation therapy, both within the
working group and the wider Australian/New Zealand
respiratory community, we completed a systematic
review of the relevant literature for this section and
used the GRADE process to move from evidence to
recommendation.25 The risk of bias was assessed using
the Cochrane Risk of Bias tool for randomized trials.26
The methodologist created evidence proﬁles for each
outcome of interest, which categorized the certainty of
evidence as high, moderate, low or very low. The pan-
ellists reviewed the evidence tables (Appendix S2 in
Supplementary Information) and provided feedback.
We used the GRADE framework to move from evi-
dence to recommendation.25 This included assess-
ments regarding the balance between desirable and
undesirable consequences, patient values and prefer-
ences, costs, feasibility and acceptability of AAT aug-
mentation therapy. The panel met by teleconference to
discuss the evidence proﬁles and formulate a
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recommendation. Voting on this recommendation was
conducted anonymously online.
DIAGNOSIS OF AATD
Who should be tested for AATD?
What are the characteristics of patients most
likely to have AATD?
Patients with AATD most often present with dyspnoea
and to a lesser extent cough and wheeze.13,27 Lung
disease in AATD is characteristically premature
(<45 years), pan-lobular emphysema with lower zone
predominance; however, upper zone predominance of
emphysema and bronchiectasis and partially reversible
airﬂow obstruction are also well recognized.3,27,28 The
World Health Organization (WHO) recommendations,
which are supported by the European and North Ameri-
can guidelines for AATD management, are that all adults
with chronic airﬂow obstruction or assumed diagnosis of
adult-onset asthma be screened for AATD, although local
and international asthma guidelines do not make a simi-
lar recommendation.1,12,29–33 We suggest that AATD test-
ing should be considered in patients with asthma when
clinically relevant, particularly in patients with persistent
airﬂow limitation, emphysema disproportionate to the
smoking history or in the presence of liver or skin
disease.
Lung disease is seen in the severely deﬁcient patients,
most commonly PiZZ, but also rarer alleles, either
homozygous or heterozygous with another severely deﬁ-
cient allele such as PiMmalton or Pi Null variants.3,13,27,34
Lung disease in AATD, although common in never-
smokers, is much more common, occurs earlier, is more
severe and progresses more rapidly in smokers. A sum-
mary of the progression of emphysema in AATD
reported that in PiZZ siblings of index cases, emphy-
sema occurred in 90% of smokers and 65% of non-
smokers.3,34 Annual loss of forced expiratory volume in
1 s (FEV1) in AATD is 23–316 mL with the greater losses
associated with smoking, male gender, age between
30 and 44, FEV1 between 35% and 79% predicted,
reduced AAT levels and airway responsiveness.3,35 This
highly variable decline in FEV1 has been shown to
exceed that consistent with normal ageing in 76% and
42% of those with and without established COPD,
respectively.36 PiMZ heterozygotes have an increased
risk of obstructive lung disease in smokers but not in
non-smokers.37,38 PiSZ heterozygotes likely have an
increased risk of emphysema in smokers but the data
from studies are not conclusive.12,39,40 PiMS and PiSS
phenotypes are not at increased disease risk.39,41,42
Lung function in AATD is often characterized by ear-
lier reduction in gas transfer and FEV1 often declines
later in disease progression.11,27 However, similar to
other lung manifestations there is wide variability
between individuals.14,35,36,43,44 A recent study in the
United Kingdom reported a decline in gas transfer
greater than 1% predicted per year in 50% of AATD
patients with normal spirometry, whereas only 25% had
a decline in FEV1 greater than 1% predicted per year,
suggesting better sensitivity of gas transfer for detecting
progression in early disease. The difference in the two
measures was less in patients who already had COPD.36
Lung volumes help further characterize the physiological
impact of hyperinﬂation and gas trapping.6
Computed tomography (CT) lung scans help deﬁne
the pattern and extent of disease in AATD even in
those with normal lung function.6,45 CT lung densitom-
etry is currently a valuable research tool in quantitating
emphysema in AATD studies but its role in patient
management remains unclear.6,12,46
What are the reasons for testing for AATD?
Identiﬁcation of patients with or at risk of lung disease
(severely deﬁcient patients, PiMZ and PiSZ heterozygotes)
associated with AATD prompts genetic counselling (see
section AAT augmentation therapy) and advice regarding
additional risk factors such as smoking and occupational
exposures.3,6,11,12,15 Identiﬁcation of individuals for consid-
eration of speciﬁc treatment, should it become available,
or clinical trials for speciﬁc treatment of AATD, is impor-
tant.3,6,12,15 Furthermore, identiﬁcation of at-risk pheno-
types for liver disease (e.g. PiZ and PiMmalton) leads to
recommendations regarding reduction of exposure to
hepatotoxins, relevant vaccinations and monitoring of
progression of disease and development of complications,
especially hepatocellular carcinoma.3,6,12,15 Identiﬁcation
of AATD in necrotizing panniculitis and granulomatosis
with polyangiitis allows better understanding of the path-
ogenesis of their disease and may lead to speciﬁc
therapies and/or involvement in clinical trials. Under-
standing disease progression and disease associations is
enhanced by monitoring those with known AATD and
AAT variation.
Has screening for AATD in patients at risk
shown to improve clinical outcomes?
There are limited data on the clinical beneﬁt due to
screening of relatives of index cases or targeted screening
of potential AATD patients. The diagnosis of AATD in
patients with obstructive lung disease allows consider-
ation of speciﬁc treatment or clinical trials of speciﬁc
treatment (see section Diagnosis of AATD). Screening for
liver disease helps to identify patients at higher risk of
developing liver complications who may beneﬁt from
closer surveillance.47,48 Data from neonatal screening
studies suggest that awareness of the deﬁciency reduces
smoking behaviour in patients with identiﬁed AATD;
however, screening increases parental stress and can
have a negative impact on parent–child relationships.49,50
Summary
• Clinical and physiological presentation of
AATD is variable.
• Testing for AATD should be considered in
all patients with chronic airﬂow obstruction.
• Testing for AATD should be considered in
asthma patients with persistent airﬂow limita-
tion, emphysema disproportionate to the
smoking history or in the presence of liver or
skin disease.
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• Baseline tests in AATD-related lung disease
should include spirometry, lung volumes,
gas transfer and CT chest scan.
• Identiﬁcation of AATD patients allows inter-
ventions to reduce risk of disease, consider
genetic counselling, monitor disease progres-
sion and associations and offer speciﬁc
treatments.
• Demonstrably improved clinical outcomes
from screening for AATD are limited.
How do we make the diagnosis of AATD?
What are the available tests?
AATD is diagnosed by a combination of serum AAT
levels, AAT phenotyping and/or AAT genotyping (most
commonly by polymerase chain reaction or PCR)
and/or AAT gene sequencing. More than 150 AAT vari-
ants have been described.51 Most have been identiﬁed
by isoelectric focusing (IEF) and many further charac-
terized by gene sequencing.3,6,11,12,15
AAT levels. AAT levels are usually measured on
serum by nephelometry.1,3,12 Normal levels of AAT vary
depending on the test used. For nephelometry, a level
below 1.1 g/L usually deﬁnes patients with at least one
deﬁciency allele.4,14 As AAT is an acute phase reactant,
borderline levels or levels which do not concur with
clinical impression should lead phenotypic or geno-
typic analysis.11 AAT and C-reactive protein (CRP)
levels are measured concurrently: this may identify
patients with an inﬂammatory state potentially affecting
AAT levels.3,12
Severely deﬁcient phenotypes, most commonly PiZZ
but also Pinullnull, Znull and some rarer variants, usu-
ally have levels of AAT below 0.5 g/L.4 Intermediate
deﬁciency phenotypes (PiMS, PiSS, PiMZ and PiSZ in
order of decreasing levels with overlap) have levels of
AAT between 0.5 and 1.4 g/L. PiMS individuals can
have levels within the normal range and some with the
PiSZ phenotype have levels below 0.5 g/L. The sensitiv-
ity and speciﬁcity of AAT levels in determining AAT-
deﬁcient alleles depends on the cut-off value for deﬁn-
ing deﬁciency. A level below 1.1 g/L will capture most
carriers of the most common deﬁciency alleles, S
and Z, as opposed to PiMM individuals (sensitivity:
73.4%, speciﬁcity: 88.5%).4,12 Some AAT types are dys-
functional (e.g. Z and F) so AAT levels do not truly
reﬂect the protective capacity of the protein.3,13
AAT phenotyping. AAT phenotype is determined by
IEF. The variants of AAT denoted A–Z migrate differ-
ently in the IEF gel at pH 4–5. The Z protein, which
folds incorrectly and forms aggregates, moves most
slowly whilst F, for example, moves quickly. The most
common M variants migrate in the middle of the gel.
Some rarer M variants are difﬁcult to distinguish from
the common variants on IEF, and the null alleles pro-
duce no AAT protein in the serum, so that as with AAT
levels if IEF-deﬁned AAT phenotype does not seem to
coincide with AAT levels then genotyping or gene
sequencing is needed to deﬁne the variant.1,3,13
AAT genotyping. AAT genotyping is usually done by
PCR. It can only test for those variants for which PCR
primers are available.52,53 There are now methods avail-
able to test multiple alleles covering more than 99% of
patients with abnormal alleles.54 These tests can be under-
taken on buccal swabs or dried blood spots. It is expected
that these methods will become available in Australia.
When available, this approach would become the pre-
ferred second test after AAT levels (as opposed to IEF).3,6,12
AAT gene sequencing. Gene sequencing has become
more practical with newer techniques but remains
highly specialized and is generally used only to charac-
terize rare variants in situations where, after AAT levels,
AAT phenotype and possibly genotype, a high index of
suspicion of a deﬁciency variant remains. This would
most commonly be with a null variant.6,12
What is the sequence of tests?
The ﬁrst screening test should be AAT levels (and CRP)
followed by IEF or genotyping (if available) if there is
concern for deﬁciency.1,3,4,11,12 Gene sequencing might
be undertaken if there is still a suspicion of deﬁciency
variant. It has been suggested that if a PiMM pheno-
type has AAT levels less than 0.9 g/L or a PiMZ or PiMS
phenotype has levels less than 0.7 g/L, then gene
sequencing should be undertaken to search for rare
deﬁciency alleles. The vast majority of variants will be
captured by this approach with the exception of very
rare gene deletions and intron mutations.4,11,12
Summary
• AAT levels can determine who should have fur-
ther testing with a high degree of sensitivity and
speciﬁcity and should bemeasured with CRP.
• AAT phenotyping by IEF or genotyping by
PCR should be undertaken when AAT varia-
tion is suspected after clinical assessment
and testing of AAT levels.
• IEF for AAT will be surpassed by AAT
genotyping as this technology becomes more
readily available.
• AAT gene sequencing may be used for
selected patients with suspected rare AAT
alleles not detected by IEF or genotyping.
AAT AUGMENTATION THERAPY
In patients with AATD, does augmentation
therapy improve outcomes compared to
usual care?
Introduction
AAT augmentation therapy is currently the only speciﬁc
therapy available for AATD. Augmentation therapy, so
© 2020 The Authors.
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called because it augments the circulatory concentra-
tions of AAT serum levels above a proposed protective
threshold,55,56 consists of intravenous (i.v.) therapy with
exogenous AAT protein that is harvested from pooled
blood products.57 AAT augmentation therapy was ﬁrst
approved by the United States Food and Drug Admin-
istration in 1987 for emphysema associated with severe
AATD.21 Several AAT augmentation therapy prepara-
tions are available, all of which have to be administered
intravenously, usually on a weekly basis.57
In Australia, AAT augmentation therapy was ﬁrst
approved by the Therapeutic Goods Administration in
November 2016; however, it is not subsidized by the
Australian Government. There are currently two AAT
preparations, which are listed on the Australian Regis-
ter of Therapeutic Goods and thus can be lawfully
supplied in Australia: Prolastin-C alpha 1-proteinase
inhibitor (Grifols Australia Pty Ltd, Melbourne,
Australia) and Zemaira alpha 1-proteinase inhibitor
(CSL Behring Australia Pty Ltd, Melbourne, Australia).
Medsafe, the New Zealand Medicines and Medical
Devices Safety Authority, registered Glassia alpha 1-
proteinase inhibitor (Shire New Zealand Ltd, Auckland,
New Zealand) in November 2017.
AAT augmentation therapy has been approved by
several national drug administration and safety authori-
ties based on its effect to raise AAT levels,58 without
evidence of the effectiveness of treatment based on
clinically important outcomes such as quality of life or
mortality or validated surrogate markers.59
A number of systematic reviews have been con-
ducted on the topic of treatment for AATD,60–62
including a 2016 Cochrane review, which included
three randomized controlled trials (RCT).63 The most
recent international statement on the diagnosis and
treatment of AATD was published by the European
Respiratory Society (ERS) in 201712 —the ﬁrst inter-
national statement since publication of the joint
statement on AATD by the American Thoracic Soci-
ety (ATS) and the ERS in 2003.1 The Canadian Tho-
racic Society published clinical practice guidelines
on targeted testing for AATD and augmentation ther-
apy in 2012.64 We conducted a systematic review
aiming to determine whether AAT augmentation
therapy improves health outcomes when compared
to usual care in patients with AATD.
Methods
We reviewed all studies included in the most recently
published systematic review on AAT augmentation
therapy published in May 2017, which included stud-
ies published up until April 2015.65 We updated the
literature search using the following electronic biblio-
graphic databases: Ovid MEDLINE(R) Epub Ahead of
Print, In-Process & Other Non-Indexed Citations, Ovid
MEDLINE(R) Daily, Ovid MEDLINE and Versions(R);
Embase; Cochrane Central Register of Controlled Tri-
als; and Cochrane Database of Systematic Reviews.
The literature search was conducted with the help of
an experienced research librarian. Databases were
searched from January 2015 to 12 July 2018
(we searched from January, rather than April, 2015 to
ensure that no relevant papers were missed). Details
of the search strategy can be found in Appendix S3
(Supplementary Information).
RCT and observational studies with a comparator
group published in any language that reported on the
effectiveness of AAT augmentation therapy in adults
aged 18 years or older with AATD, with or without for-
mal diagnosis of COPD, and with any smoking status
(current, ex-smoker and never-smoker), were eligible
for inclusion. Outcomes of interest were mortality,
exacerbations/lung infections, quality of life, healthcare
use (emergency department visits and hospitaliza-
tions), lung function measurements and lung density
measured by CT. We excluded studies that measured
biochemical outcomes only (e.g. plasma or serum AAT
level) and studies with no parallel comparison group
(e.g. studies that assessed the same cohort before and
after an intervention).
All titles and abstracts and the full texts of all arti-
cles identiﬁed on the basis of title and abstract were
assessed by at least two independent reviewers.
Data were extracted using a standardized form for
characteristics (author, study design, inclusion and
exclusion criteria, patient characteristics, interven-
tions, comparisons and outcomes). Outcome catego-
ries were grouped and analysed without quantitative
pooling. We then used the GRADE process to move
from evidence to recommendation as described
above.25
Results
The literature search identiﬁed 420 unique citations, of
which 43 were included for full-text review and 8 stud-
ies met the inclusion and exclusion criteria (Appendix
S4 in Supplementary Information). Appendix S5
(Supplementary Information) gives an overview of the
included studies. Three studies were RCT,60–62 one
study was an open-label extension of an RCT46 and four
studies were retrospective cohort studies.66–69 The evi-
dence proﬁles for each outcome can be found in
Appendix S2 (Supplementary Information).
Lung density measured by CT. Lung density on
CT as a marker of emphysema progression was
assessed in three RCT.60–62 Two RCT did not ﬁnd a
signiﬁcant difference in the change of lung density
between the group treated with AAT augmentation
and placebo, but both were underpowered.61,62 A
larger trial by Chapman et al. found a signiﬁcant dif-
ference in the annual rate of lung density loss
between the AAT augmentation group and the pla-
cebo group when lung density was measured at total
lung capacity (TLC), but not when it was measured
at functional residual capacity (FRC) or when FRC
and TLC were combined.60 A pooled estimate of the
effectiveness of AAT augmentation therapy on lung
density measured by CT in the three RCT was
obtained in a Cochrane review, which showed signiﬁ-
cantly less deterioration in the AAT augmentation
treatment group compared with the placebo group
over the 2–3 years of follow-up (pooled mean differ-
ence of change in lung density: 0.86 g/L/year (95%
CI: 0.31–1.42, P = 0.002)).63
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Lung function. Lung function parameters were the
most commonly measured outcomes in the reviewed
studies. There was no signiﬁcant difference in overall
change in FEV1 between the AAT augmentation and
control groups in three RCT60–62 and two retrospective
cohort studies.66,69 One retrospective cohort study
found that the annual decline in FEV1 in the AAT aug-
mentation group was signiﬁcantly lower than in the
untreated group (P = 0.02).68 Change in the diffusion
capacity of the lung for carbon monoxide (DLCO) and
change in the transfer coefﬁcient of the lung for carbon
monoxide (KCO) were measured in three
60–62 and two
studies,61,62 respectively, and showed no signiﬁcant dif-
ferences between groups.
Exacerbations/lung infections/hospitalizations.
Two RCT assessed the impact of AAT augmentation
therapy on exacerbations.60,62 There was no signiﬁcant
difference between the AAT augmentation group and
the control group in the frequency or duration of
exacerbations.
Quality of life. Two RCT measured changes in quality
of life using the St George’s Respiratory Questionnaire
(SGRQ) and did not ﬁnd any signiﬁcant differences
between the AAT augmentation therapy group and the
control group.60,62
Functional capacity. There was no signiﬁcant differ-
ence between AAT augmentation therapy group and
control group in functional capacity change, measured
as change in an incremental shuttle walk test in an
RCT60 and as change in 6-min walking distance
(6MWD) in an observational study.67
Mortality. None of the reviewed studies were
powered to evaluate mortality as an outcome. Of the
studies that reported deaths,60,62,66,69 one showed a sig-
niﬁcantly higher risk of mortality in the control group.66
Adverse events of AAT augmentation therapy.
In the three studies that reported adverse events (two
RCT60,62 and one open-label extension study following
an RCT46), adverse events were frequently reported in
the treatment as well as in the control group with no
signiﬁcant difference between groups.
Recommendation
• Augmentation therapy could be considered in
non-smoking patients with AATD (conditional
recommendation and low-quality evidence).
Panel vote: eight in favour, ﬁve against and four
abstain.
Justiﬁcation. The panel expressed a wide variety of
views regarding whether AAT augmentation therapy
should be offered, and we could not reach consensus
on this recommendation. We have made a conditional
recommendation because, while clinical trials do not
currently provide conclusive evidence of beneﬁt, weak-
nesses in this body of evidence mean that a beneﬁt
cannot be excluded, and some panel members noted
their own experience of improvement in patient well-
being, which they attributed to AAT augmentation ther-
apy. There are no important side effects (based on the
available evidence), although the burden of weekly
i.v. infusion and costs of treatment should be consid-
ered. AAT augmentation therapy can be considered on
a case-by-case basis using shared decision-making. We
acknowledge the resignation and withdrawal of author-
ship of one panel member on the basis that a strong
recommendation in favour of AAT augmentation ther-
apy should have been made. We also acknowledge that
some panel members felt that any potential beneﬁts of
AAT augmentation therapy were outweighed by its
substantial costs.
Subgroup considerations. People with AATD-
related COPD who continue to smoke should not be
eligible for augmentation therapy as the constituents of
cigarette smoke will likely make this therapy less effec-
tive and all RCT have excluded current smokers.
Implementation. Consideration should be given to
establishing specialist centres to oversee delivery of this
treatment.
Monitoring and evaluation. Given the uncertainty
around long-term outcomes that cannot be adequately
measured in the timeframes of clinical trials, the panel
strongly recommends that an Australian/New Zealand
registry is established. The registry should monitor
smoking status, lung function, exercise capacity and
health-related quality of life in patients with AATD-
related COPD. The registry should be independent and
should regularly report to government.
Research priorities. Further research is necessary to
establish the effect of AAT augmentation therapy on
mortality, as well as long-term effects on health-related
quality of life, exercise capacity and lung function. Fur-
ther research is also required to establish the relation-
ship between change in rate of decline of lung density
measured by CT and mortality, health-related quality
of life, exercise capacity and lung function.
LVRS AND LUNG TRANSPLANTATION
In some patients with AATD-related emphysema, dis-
ease progresses to an advanced stage where surgical
options for management should be considered. For
lung transplantation, the International Society for Heart
and Lung Transplantation (ISHLT) guidelines for the
selection of lung transplant candidates with COPD rec-
ommend referral for lung transplant assessment when
the FEV1 is <25% predicted, with listing for lung trans-
plantation recommended when the FEV1 is <20%
predicted or when there have been three or more
severe exacerbations during the preceding year, or one
severe exacerbation with acute hypercapnic respiratory
failure independent of the measured FEV1.
70 In this
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section of the position statement, we review the evi-
dence for the efﬁcacy of lung transplantation and lung
volume reduction therapies in the management of
patients with AATD-related emphysema.
In patients with AATD, does lung volume
reduction therapy improve outcomes
compared to usual care?
A 2016 Cochrane review on lung volume reduction sur-
gery (LVRS) in patients with emphysema concluded
that LVRS leads to a decrease in long-term mortality.71
Note should be made that the patients were highly
selected and the results were heavily inﬂuenced by data
from a single study (National Emphysema Treatment
Trial, NETT)72 of which only 1.3% of patients had AATD.
High rates of post-operative complications, especially
persistent air leak and pneumonia, were noted.
There are several published case series of LVRS in
patients with AATD; however, the total number of pub-
lished cases is less than 100.73–78 Overall, these case
series suggest some improvement in lung function and
symptoms at 12 months; however, the magnitude of
beneﬁt appears less than for those with conventional
smoking-related emphysema. Cassina et al. suggest
that the differences in emphysema pathology and anat-
omy in AATD could explain the difference in results.73
There is good evidence to support endobronchial lung
volume reduction with the use of endobronchial valves
in highly selected patients with cigarette smoking-related
emphysema. A 2017 Cochrane review noted short-term
(up to 1 year) improvements in lung function and dis-
ease status with high rates of adverse events especially
pneumothorax.79 It is important to note that patients
with AATD were excluded from these trials. Two case
series describing the use of endobronchial lung volume
reduction in AATD with a total of 21 patients have been
published.80,81 Short-term improvements in lung function
and symptoms were described.
Lung volume reduction by conventional surgery or
by endobronchial techniques for the management of
AATD remains controversial with very small case num-
bers, very low representation in NETT and no repre-
sentation in endobronchial controlled trials. Reported
cases are highly selected and reports of positive out-
comes may be subject to reporting and other biases.
Deﬁnitive recommendations cannot be made until
long-term data from RCT are available.
Summary
• Lung volume reduction therapy (outside of
clinical trials) is not advised for AATD due
to a lack of evidence supporting its use.
In patients with AATD, does lung
transplantation improve outcomes compared
to usual care?
Lung transplantation provides a viable treatment
option for selected patients with end-stage lung
disease. Until June 2017, almost 65 000 adult lung
transplant procedures had been reported to the ISHLT
Registry, with the number increasing year-on-year.
Now 4500 are reported each year globally.82 Until 2017,
the most common indication for lung transplantation
was COPD unrelated to AATD, accounting for approxi-
mately 30% of procedures.83 However, there have been
an increasing number of transplants performed for idi-
opathic pulmonary ﬁbrosis (IPF) over the past decade,
so that from 2017 IPF became the most common indi-
cation for lung transplantation worldwide.82 The pro-
portion of transplants performed for patients with
AATD-related emphysema has fallen from 15% 25 years
ago to under 5% over the past decade. However, the
absolute number of transplants performed has
remained relatively static.83 Another important trend
over the past two decades has been the dramatic
increase in the proportion of patients receiving bilat-
eral, rather than single, lung transplants, particularly
for obstructive lung diseases. In 2016, 94% of patients
transplanted for AATD-related emphysema received a
bilateral procedure,82 with these patients experiencing
superior survival.82 Despite this growing activity,
there have been no controlled studies performed to
determine the effectiveness of lung transplantation for
any indication, let alone for AATD-related emphy-
sema. However, multiple cohort studies describing
outcomes in individuals with severe AATD-related
emphysema who enrolled in national registries have
been published.
Quality of life
Only one study was identiﬁed that systematically inves-
tigated the impact of lung transplantation on quality of
life in patients with AATD-related emphysema. Stone
et al. studied 32 patients who were transplanted in the
United Kingdom, matched with 48 patients who did
not undergo lung transplantation selected from the UK
Registry. In 14 patients for which quality of life data
were available, lung transplantation was associated
with marked improvements in the SGRQ scores across
all domains, with the total score falling (improving)
from 67.5 (51–77.8) to 7.5 (5–13.8, P ≤ 0.01).84 In the
largest study addressing the beneﬁt of lung transplanta-
tion on quality of life in patients with a variety of dis-
ease indications, the Toronto programme found that
transplantation conferred a very large improvement in
health-related quality of life across multiple instru-
ments, with the SGRQ score falling by 46.5 (48.4–44.5)
points. Improvements in quality of life were similar
across diagnostic groups, although the number of
patients with AATD-related emphysema was very
small.85 In a multicentre US study that included
131 lung transplant recipients, large improvements in
the Medical Outcomes Study 36-Item Short-Form
Health Survey, version 2 were seen in the ﬁrst year
after transplantation. This beneﬁt was seen in all
patient groups, including those with COPD; however,
the number of patients with AATD-related emphysema
was not described.86 The Hannover group also
described very substantial improvements in health-
related quality of life for all solid organ transplant
types, including 112 lung transplant recipients.87
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Quality of life outcomes are not captured by the ISHLT
Registry. However, despite the paucity of published
studies, the magnitude and consistency of these bene-
ﬁts suggest that lung transplantation may improve
health-related quality life for patients with AATD-
related emphysema.
Survival
As there have been no randomized studies per-
formed, we are reliant on evidence from cohort stud-
ies of patients who have undergone transplantation,
matched as closely as possible with patients with sim-
ilar disease severity who did not undergo transplanta-
tion. Several cohort studies have assessed transplant-
free survival in patients with severe (generally PiZZ)
AATD-related emphysema. In the largest US study,
Stoller et al. studied 1129 National Heart, Lung, and
Blood Institute Registry participants and found that
3-year mortality was 36.2% in those with an
FEV1 < 15% predicted at enrolment, 20% in those with
FEV1 15–19% predicted and 13.5% in those with an
FEV1 between 20 and 34% predicted. The 5-year mor-
tality was 53%, 43% and 25%, respectively.88 This large
registry study hence provides reference measures for
3- and 5-year survival in patients with AATD-related
emphysema without lung transplantation, therefore
allowing an estimate of any survival beneﬁt associated
with lung transplantation.
In a large Swedish study, survival in 83 patients with
PiZZ AATD who underwent transplantation was com-
pared to that of 70 matched controls. The mean FEV1
was 22% predicted in the transplant and 23% predicted
in the control groups, respectively. Transplantation
was associated with signiﬁcantly better survival
(median 11 vs 5 years, P = 0.006) even though the
majority (75%) of patients received a single lung trans-
plant.89 As noted above, in the modern era, almost all
patients receive bilateral lung transplants with these
procedures associated with superior long-term sur-
vival.90 In a Danish registry study which included all
patients who commenced long-term oxygen therapy
(n = 21 964; n = 234 with AATD-related emphysema),
38% of the AATD patients were transplanted. There
was a signiﬁcant survival advantage (hazard ratio
(HR) for death 0.66 (95% CI: 0.44–0.99); median sur-
vival 6.0 years with, and 3.3 years without, lung trans-
plantation) for patients transplanted whilst receiving
long-term oxygen therapy.91 In a similar Swedish
study, data for 14 644 patients with COPD (284, 1.9%,
with AATD-related emphysema) who received supple-
mentary oxygen therapy were available. Median sur-
vival in the AATD-related emphysema group was very
similar to the Danish study at 7.2 years with and
3.5 years without transplantation.92 Both these groups
had a mean FEV1 of 22% predicted. The 1-, 3- and
5-year survival rates without transplantation were 84%,
55% and 36%, respectively—all signiﬁcantly lower than
registry-reported post-transplant survival rates. In
summary, these non-randomized studies appear to
support a survival beneﬁt of transplantation in patients
with AATD-related emphysema with an FEV1 <25%
predicted and/or those prescribed supplementary oxy-
gen therapy.
In contrast, in the UK registry study, 32 patients who
received 28 bilateral and 4 single lung transplants expe-
rienced similar survival after transplantation (81.3%
90-day, 74.2% 1-year, 52.9% 5-year and 45.2% 10-year
survival) compared to the non-transplanted group.84
However, the non-transplanted group had slightly bet-
ter lung function (26.3% vs 23.1%), and the early post-
transplant survival described in this study is signiﬁ-
cantly worse than that reported in the International
Thoracic Organ Transplant Registry,90 especially for
AATD where post-transplant survival is superior to all
other diagnoses (including cigarette smoking-related
emphysema) except cystic ﬁbrosis.83 The reported post-
transplant survival is also signiﬁcantly worse than that
reported by Australian transplant programmes (90%,
74% and 68% at 1, 3 and 5 years, respectively).93
Overall, the existing literature points towards a poten-
tial survival advantage for transplantation in patients
with very severe disease (FEV1 < 25% predicted, most of
whom will be receiving supplemental oxygen therapy)
as this group experiences poor survival without trans-
plantation. A survival beneﬁt of lung transplantation is
less clear for patients with better lung function.
Summary
• Lung transplantation likely provides both
quality of life and survival beneﬁts for
selected patients with very severe AATD-
related emphysema.
MANAGEMENT OF AATD (OTHER
THAN AUGMENTATION THERAPY
AND SURGERY)
Should AATD patients be treated with the
same usual care as non-AATD COPD?
Principles of non-pharmacological and pharmacologi-
cal management of COPD94–96 apply to AATD
patients,6,12 especially those patients who have chronic
airﬂow limitation. This is based on the rationale that
these management principles are relevant to COPD
patients in general, whatever the underlying cause
(AATD-related or non-AATD), as these strategies aim
to reduce symptoms, improve quality of life and pre-
vent risk of exacerbations.
Non-pharmacological management
Non-pharmacological therapy is important in the man-
agement of patients with AATD-related COPD, in addi-
tion to pharmacological, augmentation and surgical
approaches. Avoidance of active cigarette smoking, or
smoking cessation if the patient is a current smoker,
are critical preventive measures.17 Current smokers
should be supported with behavioural counselling,
together with pharmacotherapy for nicotine depen-
dence, although side effects of pharmacotherapy need
to be managed.97
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Vaccination against vaccine-preventable respiratory
viral infections is effective in COPD. Annual inﬂuenza
vaccination is recommended in people aged 65 years
and older to lower the risk of inﬂuenza-like illness,98
and in people with COPD to reduce exacerbation
rates,99 with limited, non-randomized data regarding
inﬂuenza vaccination in patients with AATD.100 The
antibody response to pneumococcal polysaccharides is
preserved in AATD, and pneumococcal vaccination
protects against community-acquired pneumonia and
reduces exacerbation rates in the wider group of all
patients with COPD.101,102
Exercise and education are important components of
the non-pharmacological management of patients with
COPD. Pulmonary rehabilitation, consisting of a com-
prehensive supervised exercise programme combined
with education, is highly recommended for symptomatic
patients with COPD, to improve exercise and quality of
life and reduce exacerbation rates.103 The beneﬁt from
the exercise component of pulmonary rehabilitation
appears to be similar in AATD-related and non-AATD-
related COPD.67 Education and self-management sup-
port, including COPD action plans,104 are useful compo-
nents of chronic disease management for COPD.
Pharmacological management
There are limited data about the use of inhaled ther-
apy, oxygen and treatment of exacerbations in COPD
patients with AATD. In one large study, implementa-
tion of a management plan associated with increased
adherence to pharmacological therapy was shown to
reduce exacerbations and unscheduled healthcare use
and improve health-related quality of life.105 A post hoc
analysis of another study suggested that inhaled corti-
costeroid could be useful in patients with AATD-
associated COPD who have persistent peripheral blood
eosinophilia.106 Prescription of inhaled therapy, oxygen
and treatment of exacerbations in AATD should be




AATD causes chronic hepatitis and its sequelae includ-
ing liver ﬁbrosis, cirrhosis and hepatocellular carci-
noma.107 In PiZZ individuals, AAT protein misfolding
favours polymerization within the endoplasmic reticu-
lum, inhibits its secretion and leads to accumulation in
hepatocytes resulting in apoptosis, upregulation of the
inﬂammatory cascade and ensuing ﬁbrogenesis and
hepatocarcinogenesis.108
The ATS and ERS suggest monitoring liver function
annually, acknowledging an evidence-based testing
protocol is yet to be established.1 A recent large study
of adults with AATD caused by the PiZZ mutation
showed signiﬁcant liver ﬁbrosis in 20–36% of individ-
uals on non-invasive testing and no evidence of a rela-
tionship between lung function and liver ﬁbrosis.109
While increased age, male sex, elevated liver enzymes
and low platelet numbers are associated with increased
liver ﬁbrosis, the damage in AATD is mostly clinically
silent and often without elevated liver enzymes even in
the setting of advanced liver disease.109,110 Therefore,
the diagnosis of AATD-related liver disease may be del-
ayed until the identiﬁcation of a signiﬁcant event such
as the development of liver cirrhosis or hepatocellular
cancer, which are associated with a poor prognosis.107
Liver biopsy is the gold standard for staging
liver ﬁbrosis but is unsuitable for the screening or
follow-up of asymptomatic patients due to the risk of
complications, pain and sampling error.111–113 Transient
tissue liver elastography, magnetic resonance
elastography and ultrasound elastography are increas-
ingly used for non-invasive assessment of liver ﬁbrosis.
These modalities have been shown to have similar
accuracy compared to others in screening for the pres-
ence of signiﬁcant liver ﬁbrosis in AATD and to identify
patients at higher risk of developing liver complications
who may beneﬁt from closer surveillance.47,48,109 In
patients with AATD and established cirrhosis, six-
monthly targeted testing for hepatocellular carcinoma
with ultrasound examination of the liver together with
serum alpha fetoprotein has been recommended.114
Although i.v. augmentation therapy of pooled human
AAT protein is available as a supportive therapy for
adults with lung disease, it is not recommended in
patients with liver disease as the mechanism of liver
injury is the accumulation of defective AAT in hepato-
cytes rather than anti-protease deﬁciency. Currently,
there is no effective treatment for AATD-related liver
disease except for liver transplantation. Recipients
express the donor phenotype and therefore they do not
experience recurrence of liver disease. In addition, the
progression of lung disease is halted, and both adults
and children with AATD have excellent overall survival
post-liver transplant at 5 years >85%.115,116 Management
also focuses on supportive measures such as nutrition,
bone health and mental health to reduce the complica-
tions of chronic liver disease. Encouragingly, current
research is exploring several innovative small molecule
and gene-based strategies which are now in clinical tri-
als and aim to reduce proteotoxicity and maintain pro-
tein homeostasis in the liver.117
Genetic counselling
It is important that patients and families understand the
medical, psychological and familial implications associ-
ated with a diagnosis of AATD. Close relatives of individ-
uals with AATD have an increased risk of carrying at-
risk alleles and should be offered genetic counselling
and testing for AATD.6,12,51,118 We recommend referral to
a genetic counselling service (details of local services are
available from the Australasian Society of Genetic Coun-
sellors at hgsa.org.au/asgc), which provides interpreta-
tion of family and medical histories, education about
inheritance and testing, and counselling to promote
informed choices and adaptation to the disease or risk
of its development in family members.119
Summary
• Smoking cessation is critically important in
all individuals with AATD whether they have
COPD.
Respirology (2020) © 2020 The Authors.
Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Paciﬁc Society of Respirology.
AATD diagnosis and treatment 9
• Patients with AATD-related COPD should be
considered for treatment according to the
principles of management of COPD in
general.
• Patients with AATD should be monitored for
liver involvement with liver biochemistry;
monitoring with ultrasound and non-
invasive modes of ﬁbrosis assessment
should be considered.
• Individuals with AATD-related lung and
liver disease should be jointly managed by
respiratory physicians and hepatologists.
• Referral of individuals with AATD for
genetic counselling is recommended.
• First-degree relatives of individuals with
AATD patient should be offered genetic
counselling and testing for AATD.
How should we monitor disease progression
in AATD?
Progression of symptoms and disease markers is highly
variable in people with AATD, being inﬂuenced by cur-
rent smoking, presence of asthma and bronchiectasis,
and other gene–environmental interactions.12
Lung function tests
Lung function, as measured by FEV1 and DLCO natu-
rally declines with age in the general population; how-
ever, decline in lung function can be accelerated in
some people with AATD.36 Although lung function
measures are often variable and may not be fully
sensitive to changes in people with AATD,12 they are
easy to perform and have reasonable utility in
COPD.94–96 Spirometry and DLCO may be considered
for yearly follow-up to detect accelerated physiological
decline.
Other tests
Whilst measurement of lung density on CT has been a
sensitive tool to detect differences in rate of change of
emphysema in research trials,120 there is insufﬁcient
evidence for regular follow-up CT chest scans in the
routine management of patients with AATD.
Summary
• Lung function testing (annual spirometry
and DLCO) is suggested for monitoring dis-
ease progression in people with AATD-
related COPD.
How should we care for patients
heterozygous for AATD?
The frequency of MZ individuals in Australia and
New Zealand is similar to the 2–5% reported in other
populations with signiﬁcant European descent but it
may be greater than this among New Zealand Maori
and lower among Australian Aboriginal peoples.7,121,122
Serum AAT levels are reduced to approximately 60%
of those found in MM individuals.4 The risk of COPD
in MZ compared with MM individuals has previously
been investigated with mixed results but more
recent studies have provided strong evidence of
increased risk in cigarette-smoking members of this
population.37,38,123,124
The frequency of SZ individuals is much lower than
that of MZ individuals122 and serum AAT levels are
reduced to around 40% of those found in MM individ-
uals.4 The risk of COPD is not yet well deﬁned but
studies suggest that it is increased in SZ individuals
compared to their MM counterparts and more so in
cigarette smokers.39,125 The risk of COPD in individuals
heterozygous for other AATD mutations is unclear
because of their rarity.
The clinical management of individuals heterozygous
for AATD remains unclear. While smoking avoidance
and cessation should be strongly encouraged, there is
no evidence, at present, for ongoing monitoring of
those who continue to smoke. In those with COPD,
there is no evidence for a differing approach from
usual care or for AAT augmentation therapy.
Summary
• Smoking cessation should be strongly
encouraged in individuals heterozygous for
AATD but regular follow-up is not advised.
• In COPD patients heterozygous for AATD,
we advise usual COPD care.
What support groups are available for people
with AATD?
A person’s quality of life can be seriously affected when
they are diagnosed with AATD. Studies of people with
non-communicable lung conditions have found there are
many unmet needs that impairs their well-being.126,127
There are many types of support available including psy-
chological, social and multidisciplinary care to help peo-
ple self-manage their disease. Support that is instituted in
a timely manner and appropriate for that person can sig-
niﬁcantly improve their everyday life.128
The Alpha-1 Association of Australia (AAA) (alpha1.
org.au) provides information and support for people
with this disease and their families. Online discussions
forums offer people with AATD the opportunity to
receive peer support, discuss challenges and problems
and engage in advocacy. Additional opportunities for
face-to-face support facilitated by the Lung Foundation
of Australia can be found through their patient support
groups (lungfoundation.com.au).
Summary
• The AAA and the Lung Foundation of
Australia offer support for people with
AATD and their families.
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Should we make use of registries for people
with AATD?
We support better understanding of the disease
through the establishment of national registries for
people with AATD in Australia and New Zealand. In
other countries, they provide large data sets to research
the natural history of the disease and to evaluate new
therapies.66,68,69 This approach has the potential for
substantive improvements in the understanding and
treatment of lung disease in AATD.
Summary
• We support the establishment of national
registries for people with AATD in Australia
and New Zealand.
CONCLUDING STATEMENT
AATD remains underdiagnosed and testing should be
carefully considered in patients with chronic airﬂow
obstruction, adult-onset asthma and bronchiectasis.
Increased recognition and diagnosis of the disease
and establishment of national registries can facilitate
greater understanding of its natural history and
research into disease-speciﬁc therapies. At testing and
diagnosis, patients and their families require access to
appropriate genetic counselling services and explana-
tion of the available support services. Patients should
be considered for treatment according to the princi-
ples of management of COPD in general and moni-
tored for evidence of liver disease while AAT
augmentation therapy could be considered in non-
smoking patients.
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